Skip to main content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Prescription Drugs & Other Medical Products

Reports

Displaying 31 - 40 of 113. 10 per page. Page 4.

Advanced Search

Identifying Safety-Net Resources at Health Centers to Prevent Infectious Disease Transmission Resulting from the Opioid Epidemic

March 21, 2019
The impact of the opioid epidemic on infectious disease transmission is an important public health issue. The problem came dramatically to light in 2015 when an outbreak of new human immunodeficiency virus (HIV) infections occurred in rural Scott County, Indiana.

Using Evidence to Drive Decision-Making in Government

March 5, 2019
This report presents the findings from the Policy Analysis and Decision-Making Capacity project, funded by the Office of Science and Data Policy within the Office of the Assistant Secretary for Planning and Evaluation at the U.S. Department of Health and Human Services.
ASPE Issue Brief

Expanding Access to Family-Centered Medication-Assisted Treatment Issue Brief

February 21, 2019
Printer Friendly Version in PDF Format (5 PDF pages)

State Policy Levers for Expanding Family-Centered Medication-Assisted Treatment

February 21, 2019
Printer Friendly Version in PDF Format (55 PDF pages)

Use of Medication-Assisted Treatment for Opioid Use Disorders in Employer-Sponsored Health Insurance: Final Report

February 11, 2019
This project assessed changes in Opioid Use Disorder (OUD) treatment utilization and expenditures in the employer-sponsored private health insurance market at two timepoints, 2006-2007 and 2014-2015, that mark the periods before and after implementation of the Mental Health Parity and Addiction Equity Act (MHPAEA), the Affordable Care Act, the introduction and expanded use of new opioid treatme

Use of Medication-Assisted Treatment for Opioid Use Disorders in Employer-Sponsored Health Insurance: Out-of-Pocket Costs

February 11, 2019
This project assessed changes in opioid use disorder (OUD) treatment utilization and expenditures in the employer-sponsored private health insurance market during 2007 and 2014.

Prescription Drug Pricing: ASPE Resources Related to Safe Harbor Rule

January 31, 2019
Department of Health and Human Services Secretary Alex Azar and Inspector General Daniel Levinson have issued a proposed rule, “Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in

Medication-Assisted Treatment for Opioid Use Disorder in the Child Welfare Context: Challenges and Opportunities

November 26, 2018
This brief describes four key challenges related to the use of medication-assisted treatment (MAT) in child welfare contexts for parents with opioid use disorder. It draws upon results from a mixed methods study examining how substance use affects child welfare systems across the country. Key challenges discussed include:
ASPE Issue Brief

Using Telehealth to Support Opioid Use Disorder Treatment Issue Brief

October 31, 2018
This Issue Brief was informed by an ASPE-funded study conducted by RTI International that assessed the use of telehealth to identify and manage SUDs in rural areas. The final research brief included an environmental scan and site visits with participants that represented a wide range of telehealth experiences throughout the country.

Comparison of U.S. and International Prices for Top Medicare Part B Drugs by Total Expenditures

October 24, 2018
The prices charged by drug manufacturers to wholesalers and distributors (commonly referred to as exmanufacturers prices) in the United States are 1.8 times higher than in other countries for the top drugs by total expenditures separately paid under Medicare Part B. U.S. prices were higher for most of the drugs included in the analysis, and U.S.